Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non‐remission acute myeloid leukaemia: A nationwide retrospective study

医学 累积发病率 危险系数 内科学 移植 造血干细胞移植 脐带血 入射(几何) 队列 置信区间 回顾性队列研究 倾向得分匹配 外科 光学 物理
作者
Kensuke Matsuda,Takaaki Konuma,Kyoko Fuse,Masayoshi Masuko,Koji Kawamura,Masahiro Hirayama,Naoyuki Uchida,Kazuhiro Ikegame,Atsushi Wake,Tetsuya Eto,Noriko Doki,Shigesaburo Miyakoshi,Masatsugu Tanaka,Satoshi Takahashi,Makoto Onizuka,Koji Kato,Takafumi Kimura,Tatsuo Ichinohe,Nobuki Takayama,Hikaru Kobayashi,Hirohisa Nakamae,Yoshiko Atsuta,Junya Kanda,Masamitsu Yanada
出处
期刊:British Journal of Haematology [Wiley]
卷期号:201 (1): 106-113 被引量:13
标识
DOI:10.1111/bjh.18530
摘要

Summary Allogeneic haematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for some patients with acute myeloid leukaemia (AML) who are refractory to chemotherapy. Cord blood transplantation (CBT) is a reasonable option in such cases because of its rapid availability. Recently, a growing number of human leucocyte antigen (HLA)‐haploidentical related donor HSCTs (haplo‐HSCTs) have been performed, although its effectiveness remains undetermined. Using the Japanese nationwide transplantation registry data, we identified 2438 patients aged ≥16 years who received CBT or haplo‐HSCT as their first transplant for non‐remission AML between January 2008 and December 2018. After 2:1 propensity score matching, 918 patients in the CBT group and 459 patients in the haplo‐HSCT group were selected. In this matched cohort, no significant difference in overall survival (OS) was observed between the CBT and haplo‐HSCT groups (hazard ratio [HR] of haplo‐HSCT to CBT 1.02, 95% confidence interval [CI] 0.89–1.16). Similarly, no significant difference in the cumulative incidence of relapse (HR 1.09, 95% CI 0.93–1.28) or non‐relapse mortality (HR 0.94, 95% CI 0.76–1.18). Subgroup analysis showed that CBT was significantly associated with preferable OS in patients receiving myeloablative conditioning. Our data showed comparable outcomes between haplo‐HSCT and CBT recipients with non‐remission AML.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
WALLE完成签到 ,获得积分10
1秒前
2秒前
2秒前
喵叽完成签到,获得积分10
2秒前
852应助泡面加蛋采纳,获得10
2秒前
沛沛完成签到,获得积分20
3秒前
3秒前
Ava应助高歌猛进采纳,获得10
4秒前
Liqy完成签到,获得积分20
4秒前
6秒前
小蘑菇应助科研通管家采纳,获得10
7秒前
赘婿应助科研通管家采纳,获得10
8秒前
JamesPei应助科研通管家采纳,获得10
8秒前
我是老大应助科研通管家采纳,获得10
8秒前
852应助科研通管家采纳,获得10
8秒前
天天快乐应助科研通管家采纳,获得10
8秒前
ran完成签到,获得积分20
9秒前
marjorie给marjorie的求助进行了留言
9秒前
shenxixi123发布了新的文献求助10
9秒前
Liqy发布了新的文献求助10
11秒前
稳重的御姐完成签到,获得积分10
11秒前
北栀完成签到,获得积分20
11秒前
12秒前
12秒前
向阳花完成签到,获得积分10
13秒前
华仔应助Liqy采纳,获得10
14秒前
娃haha完成签到,获得积分10
15秒前
15秒前
jiose完成签到,获得积分10
16秒前
16秒前
17秒前
Helicopter发布了新的文献求助10
17秒前
一路硕博完成签到,获得积分10
18秒前
刘唐荣发布了新的文献求助10
18秒前
18秒前
副热带发布了新的文献求助10
19秒前
20秒前
王kk发布了新的文献求助10
20秒前
ydk发布了新的文献求助10
20秒前
风轩轩发布了新的文献求助10
21秒前
高分求助中
Sustainability in Tides Chemistry 2000
The ACS Guide to Scholarly Communication 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Pharmacogenomics: Applications to Patient Care, Third Edition 800
Gerard de Lairesse : an artist between stage and studio 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3076448
求助须知:如何正确求助?哪些是违规求助? 2729255
关于积分的说明 7508205
捐赠科研通 2377521
什么是DOI,文献DOI怎么找? 1260640
科研通“疑难数据库(出版商)”最低求助积分说明 611108
版权声明 597203